Top

Published in:

01-08-2021 | Contraception | Brief Communication

Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series

Authors: Russo Cinzia Valeria, Lanzillo Roberta, Saccà Francesco, Moccia Marcello, Carotenuto Antonio, Brescia Morra Vincenzo

Published in: Neurological Sciences | Issue 8/2021

Abstract

Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.

European Medicine Agency Lemtrada: summary of product characteristics. 2017

Abramsky O (1994) Pregnancy and multiple sclerosis. Ann Neurol 36(Suppl):S38–S41. https://doi.org/10.1002/ana.410360712CrossRefPubMed

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL, Care MS II, Investigators C (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89(11):1117–1126. https://doi.org/10.1212/WNL.0000000000004354CrossRefPubMedPubMedCentral

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3CrossRefPubMed

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14):1069–1078. https://doi.org/10.1212/WNL.0b013e31824e8ee7CrossRefPubMed

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1CrossRefPubMed

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ, Care-Ms I, Investigators C (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89(11):1107–1116. https://doi.org/10.1212/WNL.0000000000004313CrossRefPubMedPubMedCentral

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pasto L, Giannini M, Trojano M, Comi G, Amato MP, Society MSSGotIN (2018) Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks. Neurology 90(10):e823–e831. https://doi.org/10.1212/WNL.0000000000005067CrossRefPubMed

Rog D, Oh J, Chambers C, Hellwig K, McCombe P, Otero S, Margolin DH, Daizadeh N, Compston DAS (2017) Pregnancy Outcomes in patients with RRMS treated with Alemtuzumab from the clinical development program. Paper presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25–28 October 2017

10.

Leruez-Ville M, Foulon I, Pass R, Ville Y (2020) Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2020.02.018

Title: Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series
Authors: Russo Cinzia Valeria
Lanzillo Roberta
Saccà Francesco
Moccia Marcello
Carotenuto Antonio
Brescia Morra Vincenzo
Publication date: 01-08-2021
Publisher: Springer International Publishing
Keywords: Contraception
Multiple Sclerosis
Interferon
Natalizumab
Fingolimod
Alemtuzumab
Alemtuzumab
Published in: Neurological Sciences / Issue 8/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04975-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2021

Correction to: Cerebellar and cortical hypometabolism in progressive stimulus-sensitive limb myoclonus in celiac disease

Differentiation of multiple sclerosis lesions and low-grade brain tumors on MRS data: machine learning approaches

Correction to: Research on cognitive and sociocognitive functions in patients with brain tumours: a bibliometric analysis and visualization of the scientific landscape

Impact of dietary polyphenols on neuroinflammation-associated disorders

Can Systemic Immune-Inflammation Index (SII) be a prognostic factor of Bell’s palsy patients?

Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis